Clinical Trials in Edmond, Oklahoma
43 recruiting
Showing 1–20 of 42 trials
Recruiting
Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Depressive Disorder, Major
Janssen Research & Development, LLC752 enrolled205 locationsNCT06559306
Recruiting
Not Applicable
HYDRAFIL-D: HYDRogel Augmentation For Intervertebral Lumbar Discs
Degenerative Disc Disease (DDD)
ReGelTec, Inc.225 enrolled14 locationsNCT06011551
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Chronic Migraine
Merz Therapeutics GmbH780 enrolled108 locationsNCT07018713
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Episodic Migraine
Merz Therapeutics GmbH990 enrolled108 locationsNCT07018700
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Hoffmann-La Roche2,000 enrolled484 locationsNCT05878769
Recruiting
Phase 3
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled48 locationsNCT07449923
Recruiting
Phase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Pfizer252 enrolled132 locationsNCT06977581
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1152 locationsNCT07064473
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 2
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
Hypertension
Novartis Pharmaceuticals380 enrolled84 locationsNCT06857955
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Eosinophilic Asthma
Kymera Therapeutics, Inc.264 enrolled17 locationsNCT07323654
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled236 locationsNCT06676319
Recruiting
Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
wet age related macular degenerationAMDnAMD+3 more
AbbVie714 enrolled181 locationsNCT05407636
Recruiting
Phase 2
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
Asthma
AstraZeneca540 enrolled209 locationsNCT06932263
Recruiting
Phase 2
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Asthma
Sanofi900 enrolled118 locationsNCT06609239
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439